Category Archives: Transhuman News

WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors.

Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including:

Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularitys ability to procure placental stem cells, engineer potential therapies, and deploy potential treatments, positions it to harness the potential of the human placenta and operate along the entire value chain.

Celularity was formed as a new biotechnology model designed to apply the necessary expertise to harness our placenta discovery platform across a range of unmet medical needs, said Celularity Founder and Chief Executive Officer, Robert J. Hariri, MD, PhD. With the support of our investors, we are assembling proven regenerative medicine technology and expertise with the goal of developing transformative therapies for fatal and intractable diseases. Dr. Hariri was previously chairman, chief scientific officer and chief executive officer of Celgene Cellular Therapeutics and founder of Anthrogenesis Corporation, which Celgene acquired in 2002. Dr. Hariri is also the co-founder of Human Longevity, Inc.

The formation of Celularity leverages seminal work in the discovery of novel biologically active cell populations in the human placenta with broad therapeutic potential. Celularity will draw upon these proprietary and scalable discoveries that derive from the post-partum human placenta an ethical and renewable source of usable biomaterials. Celularitys development program is focused on an allogeneic platform, leveraging clinically accessible, immune-tolerant cells and biomaterials from a diverse population of informed-consent donors.

Andrew von Eschenbach, MD, among the founding members of the Celularity Board of Directors and former United States Food and Drug Administration (FDA) Commissioner and Director of the National Cancer Institute said, The pioneering work of Celularity founder Bob Hariri has unleashed the unique properties of placental derived stem cells which have renewed hope for creating safe and effective therapies for the most challenging degenerative diseases." Dr. von Eschenbach added " Celularity with its focus on accelerating innovation in regenerative medicine can become the leading catalyst for cell therapy to address many of the world's unmet medical needs."

*Interfyl is a registered trademark of Alliqua BioMedical, Inc.

Dr. Henry Ji, President and CEO of Sorrento Therapeutics, said, We are very excited to participate in the creation of Celularity together with Dr. Hariri and his scientific team as well as global leading biopharmaceutical companies, such as Celgene, Human Longevity Inc., and United Therapeutics. The potential for regenerative therapies in treating a wide array of chronic degenerative conditions is well known. We see important synergies for the oncology field and the potential to enhance our fight against malignant cancers. Celularitys technologies, assets, and resources will help advance selected Sorrento cellular therapy programs and potentially transform autologous cellular therapies into affordable and accessible allogeneic cell therapies.

About Celularity, Inc.

Celularity, headquartered in Warren, New Jersey, is a biotechnology company with proprietary, leading-edge technology and Intellectual Property to harness the power of the placenta. Their medicine asset portfolio consists of more than 200 issued or pending patents as well as pre-clinical and clinical assets including CAR constructs for allogeneic CAR-T/NK products, licenses of 100+ immunotherapy assets, and commercial stage biosourcing and functional regeneration businesses. For more information, please visit http://www.celularity.com. Follow Celularity on Social Media:@Celularity.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.

About Sorrento Therapeutics

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for immuno-oncology, inflammation and autoimmune diseases. Sorrento's lead product candidates include immunotherapies focused on the treatment of both solid tumors and hematological malignancies, as well as late stage pain products. For more information, please visit http://sorrentotherapeutics.com

About Human Longevity, Inc.

Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company creating the worlds largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize health. In addition to the HLIQ Whole Genome and HLIQ Oncology, HLIs business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com

Originally posted here:
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform - Business Wire (press release)

Robert Hariri

One of the best known names in regenerative medicine is launching a new biotech with assets and cash coming from a range of marquee companies that includes Celgene.

The founder of the Warren, NJ-based upstart is Robert Hariri, a co-founder at Craig Venters Human Longevity. Hariri ran Anthrogenesis when Celgene bought it out 15 years ago, then headed Celgene Cellular Therapeutics for a period. Along the way he developed projects using stem cells derived from human placentas and inked collaborations between some of the key players, including Celgene.

Now, Hariri says he has gathered together preclinical assets related to immuno-oncology as well as regenerative tech for chronic and degenerative diseases. He raised an unspecified amount of money from a group that includes Sorrento Therapeutics, United Therapeutics and Human Longevity.

San Diego-based Sorrento passed along some IP on cell therapies and I/O, while United CEO Martine Rothblatt and Venter both have expressed an avid interest in anti-aging technologies.

Sorrento CEO Henry Ji

While stem cell R&D has gone through its boom and bust period, a number of prominent players are taking what theyre learned and headed back to the clinic, looking to succeed where others have failed. Adding I/O to the mix will also help enhance its image.

Hariri clearly wants to start out with some big names on the board, which includes former FDA commissioner Andrew von Eschenbach.

Sorrento CEO Henry Ji noted:

The potential for regenerative therapies in treating a wide array of chronic degenerative conditions is well known. We see important synergies for the oncology field and the potential to enhance our fight against malignant cancers. Celularitys technologies, assets, and resources will help advance selected Sorrento cellular therapy programs and potentially transform autologous cellular therapies into affordable and accessible allogeneic cell therapies.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Read the rest here:
Big names, big companies back a cell therapy startup run by a high-profile regenerative med expert - Endpoints News

Laura Deming is not your typical venture capitalist. Then again, she isnt typical in many ways.

For starters, the 23-year-old, New Zealand native was home schooled, developing along the way a love of math and physics and, perhaps most interestingly, the biology of aging. In fact, she became so preoccupied with the latter that at age 11, Deming wrote to Cynthia Kenyon, a renowned molecular biologist who specializes in the genetics of aging, asking if she could visit Kenyons San Francisco lab during a family trip to the Bay Area. Kenyon said yes. When, soon after the visit, Deming asked if she could work in the lab, Kenyon said yes again.

Demings family moved to the U.S. to make it possible, and its highly doubtful they regret the decision. Indeed, by age 14, Deming was a student at MIT, and two years after that at the tender age of 16 she was a college drop-out, having been accepted into Peter Thiels two-year-old Thiel Fellowship program, which gives $100,000 to young people who want to build new things.

Often, those new things evolve along the way. Not for Deming, who pitched the idea of a venture fund that would support aging-related startups, and has since turned that early concept intoLongevity Fund, an early-stage venture outfit that just closed its second fund with $22 million.

Earlier today we caught up with Deming to learn more about her path and which technologies shes betting on to extend the human lifespan.

TC: Its incredible that this all started with an email to a UCSF professor.

LD: [Cynthia Kenyon] is the most amazing person Ill ever meet.

TC: What did you do in her lab, exactly?

LD: We were working with tiny, see-through worms. You put them on a plate of jelly and you see what happens if you change their genetic material. Do they live longer or die faster? If you starve them, they live longer. If you starve worms and also turn off certain genes, could you get them to live even longer? I was nave, but I really wanted to make the longest-living worms ever. [Laughs.]

TC: What did you study at MIT?

LD: I majored in physics actually, but I continued to work in a couple of labs, including [one overseen by] Lenny Guarente [a biologist known for his research on lifespan extension]. It was a lot of fun. I thought Id be a scientist, but a grad student familiar with the Thiel fellowship told me I should apply and I did. Its funny, one of the directors of the [Thiel] program told me recently that he thought Id fail, even though he was very supportive. After we closed the first fund, he was like, I never thought that would work out.

TC: Why?

LD: In part because not long ago, if you talked with most VCs about aging, they didnt think there was anything there. I think aging is such a young science, they hadnt heard about it. Meanwhile, I care a lot about it, and though we dont know if itll work or not, its not unlike [biotech companies trying to tackle] cancer in that way, and if you believe in cancer companies, you should also care about aging companies.

TC: How much did you raise for that first fund?

LD: A grand total of $4 million, and I was very proud of this. To be honest, Id assumed $100,000 was enough to build a fund until I arrived in San Francisco and realized it was really enough to live on for two years. When I started fundraising, I was 17 too young to legally sign contracts. Id never managed money before. But I could talk to people about the science and got them on board with that. In the end, we had great anchor investors come together, and we invested in five companies that kind of proved out the strategy.

TC: Were one of those anchor investors Peter Thiel?

LD: We dont really talk about our LPs.

TC: You say we, though youre the sole general partner of Longevity. Is that correct?

LD: Yes, but I have a lot of back-office support. The way Longevity is structured, Im also able to pull in the best people who have expertise from different domains, so its not one person who looks at all the deals.

TC: And these advisors get a stake in the company?

LD: Sometimes. Others especially grad students like to be paid up front. Well find the best incentive for that individual and work with that.

TC: One of your portfolio companies is Unity Biotechnology, a company thats trying to reverse aging through therapeutics. Didnt it just raise a giant Series B round this week?

LD: It did. All of the companies in that portfolio have [at least] raised Series A rounds of $30 million or more to get to that proof of concept.

TC: Given the amounts involved, is the plan to form special purpose vehicles, or SPVs, around your break-out winners?

LD:We like to help LPs follow on, so we look to do that in whatever way makes sense for both parties. With Unity, we put in money as early as possible because Ned Davis, who runs the company, is amazing and we thought its aging thesis would succeed.

TC: How many companies do you expect to fund with your newly closed fund?

LD: Eight to 10 companies.

TC: Do you think your work will be harder, given that investors seem to be paying much more attention to aging suddenly?

LD: No. With our first fund, we spent up to six months with each deal, tracking the company before it was even raising. Its something LPs really value from us; they know when they invest in something that they dont need to re-do the diligence, that weve already looked at a bunch of stuff and we know this is the best possible investment in [a particular vertical].

Earlier, our biggest challenge was getting other investors on board and convincing them that aging has become a place to play. Now thats a non-issue, which is great. Our job is to help the companies get other investors on board, so its wonderful to see excitement in the space begin to build.

TC: You look at a lot of technologies. I have to ask: do you find these new blood transfusion startupsas interesting as the writers of HBOs Silicon Valley?

LD: [Laughs.] While scientifically interesting, I think they get a little over-discussed in the press because of that vampirism. Its not as sexy to talk about new genetic regulatory elements that control the aging process. Thats not going to get as many clicks as a story about drinking the blood of your five-year-old.

Read the rest here:
This 23-year-old just closed her second fund which is focused on aging with $22 million - TechCrunch

By Tom Purcell Cagle Cartoons

A 125-year life expectancy for human beings? I have zero desire to stick around that long.

Ah, yes, you speak of a debate among scientists over human longevity. I read about it at Business Insider. Some scientists argue that the maximum age humans may live is 115 years, whereas others argue that 125 years is possible.

A hundred and twenty-five years of watching Republicans and Democrats going at it? The heck with that.

Living is rife with challenges, to be sure. But living a long life has its upsides. Wouldnt you want to visit your parents and other family members for a lot more years than most of us are able? Wouldnt you like to see them all at a Sunday dinner several more times than most human beings are able?

Maybe with your family. My family has taken years off of my life!

I see, but wouldnt it be awesome if some of our finest human beings could stick around longer? Don Rickles, one of the greatest entertainers ever, died this year at 91. How great would it be to keep him around for two more decades?

True, but if Rickles were to stick around longer, that means annoying celebrities would stick around, too, and keep yapping at us every time a Republican becomes president.

There are other upsides to a longer life. What if we could keep our greatest minds around longer? Where would the world be if Einstein had another 25 years to unlock the mysteries of the universe?

But what if he figured out ways to extend human life even further, which would require me and the wife to have to keep coming up with new things to bicker about? Who has that kind of energy?

The downsides are a fair point. As people live longer, they could overburden government programs, such as Social Security. Where would we get all the money to support them?

How about we especially extend the lives of the rich so we can take them to the cleaners?

And living is expensive. If you live to 125, how will you pay for your housing and food and everyday expenses?

Thank goodness McDonalds is always hiring, but I for one have no desire to flip burgers at the age of 125.

The costs of medical care are too high for millions now. I imagine that at 125 years of age, ones medical bills would be difficult to manage.

Look, as a middle-aged guy, who is already showing signs of fatigue, here is what I know about living. Life is largely made up of colds, bills, speeding tickets and people who let you down. These experiences are connected together by a series of mundane tasks.

Did anyone tell you how cheerful you can be? Go on.

Well, these drudgeries are occasionally interrupted by a wonderful meal, a really good laugh with friends or a romantic evening with a lovely woman. Then the mundane stuff starts all over again. Who wants 125 years of that?

A lot of people do. The human lifespan has improved significantly in the past few generations. Millions are living healthy lives beyond the age of 80 today, and, when they were younger, few of them expected to live that long. Why not live relatively good lives until 125?

Because then Id really worry about my slacker son.

Why?

Hes 35 years old and still living at home. If we drastically extend lifespans, my wife will have to tell him: Son, youre 100 years old! When are you going to move out of the basement and get a job?

Tom Purcell (Tom@TomPurcell.com) is a columnist for the Pittsburgh Tribune-Review. He writes for the Cagle Cartoons newspaper syndicate.

The rest is here:
Purcell: Living to 125: Too much of a good thing? - The Ledger

Tom Brady appears to be confident heading into the 2017 season. In a recent interview with Fox Sports Jay Glazer, Brady said some aspects of football are easier for him now than ever before. Thats not a ludicrous statement, considering Brady has won two Super Bowls over the last three years and played some of the best football of his career.

But human hot air balloonDoug Gottlieb, who now yaps on Fox Sports Radio, isnt buying it. Gottlieb called out Brady Friday, citing the Patriots quarterbacks poor first half against the Falcons in Super Bowl LI. If the Patriots didnt come back and defeat the Falcons, Gottlieb says, we would view Brady differently right now. Brady threw one interception and posted a 78.1 quarterback rating in the first three quarters of the game.

"I watched the Super Bowl. In the first half, he was bad, Gottlieb said on The Herd with Colin Cowherd.He did throw a pick-six. While we want to remember only that they came from behind, if the Atlanta Falcons had just taken a knee, if they had just run the football into the ground and not fumbled it, made one field goal up 28-3 after Julio Jones catch. This narrative changes dramatically. Im not talking about the, Is he the greatest of all-time? narrative. Im talking about, think of how we view the New England Patriots camp and Tom Bradys longevity. Now you have people saying, Look, he could go forever.

Gottlieb is correct: the Falcons choked away Super Bowl LI. But the Patriots were able to capitalize on every mistake, largely thanks to Bradys otherworldlyperformance. He completed 22 of 28 passes for 246 yards and one touchdown (115.2 QBR) to lead the Patriots to the historic come-from-behind victory.

But Gottlieb disregards those numbers in his rant, focusing entirely on Bradys early mistakes. The truth is, as accomplished as he is, as experienced as he is, he did not look good at all, Gottlieb explained. He was rattled. And I will grant you, they didnt have Rob Gronkowski, whos his best target. Hes one of the elite players in the NFL. They didnt have him for that entire game, and that would cause any quarterback to be a little bit scattered with where they wanted to go with the football. But if you want to tell me, 'Ive seen everything, Im better now, its easier than it used to be.' Well, why wasnt it easier against the Atlanta Falcons?

Perhaps Gottlieb stopped watching the game early, much like President Donald Trump. Thats one of the only plausible explanations for his disregard of Bradys play in the fourth quarter and overtime.

The other one is that Gottlieb didnt want to let the facts get in this way of his attention-seeking screed. As a frequent offender myself, I know that strategy when I see it.

More:
Human hot air balloon Doug Gottlieb thinks everyone is being too easy on Tom Brady - WEEI.com (blog)